Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxalipiatin

Kana Nakauchi, Hitoshi Kawazoe, Risa Miyajima, Chieko Waizumi, Yuki Rokkaku, Kikue Tsuneoka, Noriko Higuchi, Mitsuko Fujiwara, Yoh Kojima, Yoshihiro Yakushijin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Venous pain induced by oxalipiatin (L-OHP) is a clinical issue related to adherence to the CapeOX regimen. To prevent L-OHP-induced venous pain, we provided nursing care to outpatients who were administered a preheated L-OHP diluted solution using a hot compress. We retrospectively evaluated the risk factors for colorectal cancer patients who had L-OHP-induced phlebitis and venous pain. Furthermore, the preventive effect of nursing care was compared between inpatients and outpatients from January 2010 to March 2012. At the L-OHP administration site, any symptoms were defined as phlebitis, whereas pain was defined as venous pain. A total of 132 treatment courses among 31 patients were evaluated. Multivariate logistic regression analysis revealed that both phlebitis and venous pain were significantly more common in female patients (adjusted odds ratio, 2.357; 95%CI: 1.053-5.418; and adjusted odds ratio, 5.754; 95%CI: 2.119-18.567, respectively). The prevalence of phlebitis and venous pain did not differ between inpatients and outpatients (phlebitis, 61.3% vs 67.7%; venous pain, 29.0% vs 19.4%). These results suggest that administration of L-OHP via a central venous route should be considered in female patients.

Original languageEnglish
Pages (from-to)1397-1400
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume42
Issue number11
Publication statusPublished - 2015 Nov 1
Externally publishedYes

Keywords

  • Oxalipiatin
  • Phlebitis
  • Risk factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxalipiatin'. Together they form a unique fingerprint.

  • Cite this

    Nakauchi, K., Kawazoe, H., Miyajima, R., Waizumi, C., Rokkaku, Y., Tsuneoka, K., Higuchi, N., Fujiwara, M., Kojima, Y., & Yakushijin, Y. (2015). Risk factors for oxaliplatin-induced phlebitis and venous pain, and evaluation of the preventive effect of preheating with a hot compress for administration of oxalipiatin. Japanese Journal of Cancer and Chemotherapy, 42(11), 1397-1400.